MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s ...

A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Biobeat Technologies has raised $50 million in a series B round to help boost the commercialization of its blood pressure ...

Sanofi has returned to U.S. artificial intelligence research biotech Earendil Labs for another significant autoimmune and ...

The June agreement established a fixed revenue-sharing model, with TME Pharma receiving a “larger share of future licensing ...

In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. | In 2025, biopharma layoffs showed ...

Right on the heels of its IPO, Insilico Medicine is starting the year with an oncology discovery and development pact with French pharma Servier.  | Right on the heels of its IPO, Insilico Medicine is ...

Koroshetz’s exit—expected Jan. 24—means that 14 of the NIH’s 27 units will be helmed by interim leaders. NINDS acting deputy ...

Pieper is now working to advance P7C3-A20 through Glengary Brain Health, a Cleveland-based company that he cofounded, according to the release. Pieper’s team had previously found that the ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of ...